537 research outputs found
Current Treatment Options in CLL
After impressive developments in recent years with the rise of new targeted agents,
chemoimmunotherapy (CIT) only plays a minor role in the treatment of patients with chronic
lymphocytic leukemia (CLL). Inhibitors of the Bruton tyrosine kinase (BTK), such as ibrutinib or
more recently acalabrutinib, are highly effective, even in poor-risk or chemo-refractory patients.
Venetoclax, an inhibitor of the anti-apoptotic BCL2 protein and, to a lesser extent, phosphoinositide-3
kinase (PI3K) delta inhibitors, add to the armamentarium of targeted agents for the treatment of
CLL. Furthermore, anti-CD20 monoclonal antibodies are used very successfully either alone or in
combination with BTK, BCL2 or PI3K inhibitors. Despite these advances, there is still an ongoing
pursuit for new therapeutic approaches in the treatment of CLL. An even bigger challenge poses the
determination of the optimal combination and sequence of those drugs. Here, we give an overview
of current treatment options in CLL, weighing the advantages and disadvantages of each approach
in the light of different clinical settings
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study
Obinutuzumab; Leucèmia limfocÃtica crònica; Malaltia residual mÃnimaObinutuzumab; Leucemia linfocÃtica crónica; Enfermedad residual mÃnimaObinutuzumab; Chronic lymphocytic leukaemia; Minimal residual diseaseThe manageable toxicity profile of obinutuzumab (GA101; G) alone or with chemotherapy in first-line (1L; fit and non-fit) and relapsed/refractory (R/R) patients with chronic lymphocytic leukaemia (CLL) was established in the primary analysis of the Phase IIIb GREEN trial (Clinicaltrials.gov: NCT01905943). The final analysis (cut-off, 31 January 2019) is reported here. Patients received G (1000 mg) alone (G-mono; fit and non-fit patients) or with chemotherapy [fludarabine and cyclophosphamide (FC; fit patients); chlorambucil (non-fit patients); bendamustine (any patient)]. Study endpoints were safety (primary) and efficacy (secondary). Subgroup analyses were performed on prognostic biomarkers in 1L CLL. Overall, 630 patients received 1L and 341 received R/R CLL treatment. At the final analysis, no new safety signals were observed [Grade ≥ 3 adverse events (AEs): 1L 82·7%, R/R 84·5%; serious AEs: 1L 58·1%, R/R 62·5%]. Neutropenia (1L 50·5%, R/R 53·4%) and thrombocytopenia (1L 14·6%, R/R 19·1%) were the most common Grade 3–5 AEs. G-mono-, G-bendamustine and G-FC-treated patients with unmutated immunoglobulin heavy chain trended towards shorter progression-free survival. Achievement of minimal residual disease negativity was greatest in 1L patients treated with G-FC. In this final analysis of the GREEN trial, the safety profile of G was consistent with current risk management strategies. Biomarker analyses supported efficacy in the specific subgroups.F. Hoffmann-La Roche Ltd
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53 mutations] before each line of treatment to allow for appropriate treatment decisions that can optimize patient outcomes. The current report reviews the diagnostic methods to better detect TP53 disruption, the role of TP53 aberrations in treatment decisions and current therapies available for patients with chronic lymphocytic leukemia carrying these abnormalities. The standardization in sequencing technologies for accurate identification of TP53 mutations and the importance of continued evaluation of TP53 aberrations throughout initial and subsequent lines of therapy remain unmet clinical needs as new therapeutic alternatives become availabl
Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is known for its strong dependency on the tumor microenvironment. We found progranulin (GRN), a protein that has been linked to inflammation and cancer, to be upregulated in the serum of CLL patients compared to healthy controls, and increased GRN levels to be associated with an increased hazard for disease progression and death. This raised the question of whether GRN is a functional driver of CLL. We observed that recombinant GRN did not directly affect viability, activation, or proliferation of primary CLL cells in vitro. However, GRN secretion was induced in co-cultures of CLL cells with stromal cells that enhanced CLL cell survival. Gene expression profiling and protein analyses revealed that primary mesenchymal stromal cells (MSCs) in co-culture with CLL cells acquire a cancer-associated fibroblast-like phenotype. Despite its upregulation in the co-cultures, GRN treatment of MSCs did not mimic this effect. To test the relevance of GRN for CLL in vivo, we made use of the Eμ-TCL1 CLL mouse model. As we detected strong GRN expression in myeloid cells, we performed adoptive transfer of Eμ-TCL1 leukemia cells to bone marrow chimeric Grn−/− mice that lack GRN in hematopoietic cells. Thereby, we observed that CLL-like disease developed comparable in Grn−/− chimeras and respective control mice. In conclusion, serum GRN is found to be strongly upregulated in CLL, which indicates potential use as a prognostic marker, but there is no evidence that elevated GRN functionally drives the disease
Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab
Patients with pre-existing comorbidities and immunosuppression are at greater risk for
SARS-CoV-2 infection and severe manifestations of COVID-19. This also includes cancer
patients, who are shown to have a poor prognosis after infection. Here, we describe the
case of a 72-year old male patient with B-cell depletion after maintenance treatment
with rituximab for non-Hodgkin-lymphoma who had a prolonged COVID-19 course and
initial false negative test results. Our case highlights the diagnostic pitfalls in diagnosing
COVID-19 in B-cell depleted patients and discuss the role of B-cell depletion in the course
and treatment of COVID-19. Furthermore, we investigated peripheral blood monocytes
and SARS-CoV-2 specific T cells in our patient. In conclusion, our case report can help
physicians to avoid diagnostic pitfalls for COVID-19 in hemato-oncological patients under
chemoimmunotherapy and tries to explain the role of B-cell depletion and SARS-CoV-2
specific T cells in this context
- …